Literature DB >> 33941120

Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification.

Chaiwat Tawarungruang1,2,3, Narong Khuntikeo2,4,5, Nittaya Chamadol2,4,6, Vallop Laopaiboon6, Jaruwan Thuanman2,3, Kavin Thinkhamrop4,7, Matthew Kelly8, Bandit Thinkhamrop9,10,11.   

Abstract

BACKGROUND: Cholangiocarcinoma (CCA) has been categorized based on tumor location as intrahepatic (ICCA), perihilar (PCCA) or distal (DCCA), and based on the morphology of the tumor of the bile duct as mass forming (MF), periductal infiltrating (PI) or intraductal (ID). To date, there is limited evidence available regarding the survival of CCA among these different anatomical and morphological classifications. This study aimed to evaluate the survival rate and median survival time after curative surgery among CCA patients according to their anatomical and morphological classifications, and to determine the association between these classifications and survival.
METHODS: This study included CCA patients who underwent curative surgery from the Cholangiocarcinoma Screening and Care Program (CASCAP), Northeast Thailand. The anatomical and morphological classifications were based on pathological findings after surgery. Survival rates of CCA and median survival time since the date of CCA surgery and 95% confidence intervals (CI) were calculated. Multiple cox regression was performed to evaluate factors associated with survival which were quantified by hazard ratios (HR) and their 95% CIs.
RESULTS: Of the 746 CCA patients, 514 had died at the completion of the study which constituted 15,643.6 person-months of data recordings. The incidence rate was 3.3 per 100 patients per month (95% CI: 3.0-3.6), with median survival time of 17.8 months (95% CI: 15.4-20.2), and 5-year survival rate of 24.6% (95% CI: 20.7-28.6). The longest median survival time was 21.8 months (95% CI: 16.3-27.3) while the highest 5-year survival rate of 34.8% (95% CI: 23.8-46.0) occurred in the DCCA group. A combination of anatomical and morphological classifications, PCCA+ID, was associated with the longest median survival time of 40.5 months (95% CI: 17.9-63.0) and the highest 5-year survival rate of 42.6% (95% CI: 25.4-58.9). The ICCA+MF combination was associated with survival (adjusted HR: 1.45; 95% CI: 1.01-2.09; P = 0.013) compared to ICCA+ID patients.
CONCLUSIONS: Among patients receiving surgical treatment, those with PCCA+ID had the highest 5-year survival rate, which was higher than in groups classified by only anatomical characteristics. Additionally, the patients with ICCA+MF tended to have unfavorable surgical outcomes. Showed the highest survival association. Therefore, further investigations into CCA imaging should focus on patients with a combination of anatomical and morphological classifications.

Entities:  

Keywords:  Anatomical; CASCAP; Cholangiocarcinoma; Classification; Morphological; Survival

Year:  2021        PMID: 33941120     DOI: 10.1186/s12885-021-08247-z

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  17 in total

Review 1.  Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas.

Authors:  James E Everhart; Constance E Ruhl
Journal:  Gastroenterology       Date:  2009-02-24       Impact factor: 22.682

2.  Cholangiocarcinoma in north east Thailand. A hospital-based study.

Authors:  A Green; T Uttaravichien; V Bhudhisawasdi; W Chartbanchachai; D B Elkins; E O Marieng; C Pairqjkul; T Dhiensiri; N Kanteekaew; M R Haswell-Elkins
Journal:  Trop Geogr Med       Date:  1991 Jan-Apr

3.  Survival rate of intrahepatic cholangiocarcinoma patients after surgical treatment in Thailand.

Authors:  Sudarat Sriputtha; Narong Khuntikeo; Supannee Promthet; Supot Kamsa-Ard
Journal:  Asian Pac J Cancer Prev       Date:  2013

Review 4.  Clinical diagnosis and staging of cholangiocarcinoma.

Authors:  Boris Blechacz; Mina Komuta; Tania Roskams; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-02       Impact factor: 46.802

5.  Pathological classification of intrahepatic cholangiocarcinoma based on a new concept.

Authors:  Yasuni Nakanuma; Yasunori Sato; Kenichi Harada; Motoko Sasaki; Jing Xu; Hiroko Ikeda
Journal:  World J Hepatol       Date:  2010-12-27

6.  Hepatic resection for intrahepatic cholangiocarcinoma: relation to gross tumor morphology.

Authors:  T Itamoto; T Asahara; K Katayama; H Nakahara; T Fukuda; M Yano; H Hino; M Nakahara; K Dohi; F Shimamoto
Journal:  Hepatogastroenterology       Date:  2001 Jul-Aug

Review 7.  Epidemiology of cholangiocarcinoma: an update focusing on risk factors.

Authors:  Hai-Rim Shin; Jin-Kyoung Oh; Eric Masuyer; Maria-Paula Curado; Veronique Bouvard; Yue-Yi Fang; Surapon Wiangnon; Banchob Sripa; Sung-Tae Hong
Journal:  Cancer Sci       Date:  2009-12-04       Impact factor: 6.716

8.  Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?

Authors:  Shahid A Khan; Shireen Emadossadaty; Nimzing G Ladep; Howard C Thomas; Paul Elliott; Simon D Taylor-Robinson; Mireille B Toledano
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

9.  Cohort profile: cholangiocarcinoma screening and care program (CASCAP).

Authors:  Narong Khuntikeo; Nittaya Chamadol; Puangrat Yongvanit; Watcharin Loilome; Nisana Namwat; Paiboon Sithithaworn; Ross H Andrews; Trevor N Petney; Supannee Promthet; Kavin Thinkhamrop; Chaiwat Tawarungruang; Bandit Thinkhamrop
Journal:  BMC Cancer       Date:  2015-06-09       Impact factor: 4.430

10.  Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area.

Authors:  Prakongboon Sungkasubun; Surachate Siripongsakun; Kunlayanee Akkarachinorate; Sirachat Vidhyarkorn; Akeanong Worakitsitisatorn; Thaniya Sricharunrat; Sutida Singharuksa; Rawisak Chanwat; Chairat Bunchaliew; Sirima Charoenphattharaphesat; Ruechuta Molek; Maneenop Yimyaem; Gaidganok Sornsamdang; Kamonwan Soonklang; Kasiruck Wittayasak; Chirayu U Auewarakul; Chulabhorn Mahidol
Journal:  BMC Cancer       Date:  2016-06-02       Impact factor: 4.430

View more
  8 in total

Review 1.  Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.

Authors:  Panagiotis Sarantis; Eleftheria Dikoglou Tzanetatou; Evangelia Ioakeimidou; Christos Vallilas; Theodoros Androutsakos; Christos Damaskos; Nikolaos Garmpis; Anna Garmpi; Athanasios G Papavassiliou; Michalis V Karamouzis
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Prognostic Significance of Growth Pattern in Predicting Outcome of Opisthorchis viverrini-Associated Distal Cholangiocarcinoma in Thailand.

Authors:  Waritta Kunprom; Chaiwat Aphivatanasiri; Prakasit Sa-Ngiamwibool; Sakkarn Sangkhamanon; Piyapharom Intarawichian; Walailak Bamrungkit; Malinee Thanee; Piya Prajumwongs; Watcharin Loilome; Narong Khuntikeo; Attapol Titapun; Apiwat Jareanrat; Vasin Thanasukarn; Tharatip Srisuk; Vor Luvira; Kulyada Eurboonyanun; Julaluck Promsorn; Supinda Koonmee
Journal:  Front Public Health       Date:  2022-05-16

3.  Bioinformatic Prediction of Novel Signaling Pathways of Apoptosis-inducing Factor, Mitochondrion-associated 3 (AIFM3) and Their Roles in Metastasis of Cholangiocarcinoma Cells.

Authors:  Daraporn Chua-On; Tanakorn Proungvitaya; Anchalee Techasen; Temduang Limpaiboon; Sittiruk Roytrakul; Doungdean Tummanatsakun; Norie Araki; Siriporn Proungvitaya
Journal:  Cancer Genomics Proteomics       Date:  2022 Jan-Feb       Impact factor: 4.069

4.  CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype.

Authors:  Serena Mancarella; Grazia Serino; Isabella Gigante; Antonio Cigliano; Silvia Ribback; Paola Sanese; Valentina Grossi; Cristiano Simone; Raffaele Armentano; Matthias Evert; Diego F Calvisi; Gianluigi Giannelli
Journal:  J Exp Clin Cancer Res       Date:  2022-02-16

5.  The Effects of Ibuprofen, Naproxen and Diclofenac on cell Apoptosis, Cell Proliferation and Histology Changes in Human Cholangiocarcinoma Cell Lines.

Authors:  Ratana Leksomboon; Kamonrot Kumpangnil; Kanjana Pangjit; Latiporn Udomsuk
Journal:  Asian Pac J Cancer Prev       Date:  2022-04-01

Review 6.  Translational Value of Tumor-Associated Lymphangiogenesis in Cholangiocarcinoma.

Authors:  Massimiliano Cadamuro; Adriana Romanzi; Maria Guido; Samantha Sarcognato; Umberto Cillo; Enrico Gringeri; Giacomo Zanus; Mario Strazzabosco; Paolo Simioni; Erica Villa; Luca Fabris
Journal:  J Pers Med       Date:  2022-06-30

7.  Modification of the eighth AJCC/UICC staging system for perihilar cholangiocarcinoma: An alternative pathological staging system from cholangiocarcinoma-prevalent Northeast Thailand.

Authors:  Chaiwat Aphivatanasiri; Prakasit Sa-Ngiamwibool; Sakkarn Sangkhamanon; Piyapharom Intarawichian; Waritta Kunprom; Malinee Thanee; Piya Prajumwongs; Narong Khuntikeo; Attapol Titapun; Apiwat Jareanrat; Vasin Thanasukarn; Tharatip Srisuk; Vor Luvira; Kulyada Eurboonyanun; Julaluck Promsorn; Watcharin Loilome; Aileen Wee; Supinda Koonmee
Journal:  Front Med (Lausanne)       Date:  2022-09-30

8.  Rapid label-free detection of cholangiocarcinoma from human serum using Raman spectroscopy.

Authors:  Peeraya Suksuratin; Rutchanee Rodpai; Vor Luvira; Pewpan M Intapan; Wanchai Maleewong; Oranat Chuchuen
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.